January 10, 2020
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery.
The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform.
December 5, 2019
The FDA and National Institutes of Health are tapping the clinical community and a newly launched mobile platform in its search for novel infectious disease interventions.
Called CURE ID, the online data repository will allow clinicians to report instances in which existing FDA-approved drugs are used to successfully treat infections.
In particular, the tool captures clinical outcomes in cases...
July 31, 2019
Litmus Health announced yesterday the release of a new version of its device-friendly clinical research platform for the collection and analysis of real-world data.
Built with new features to help pharmaceutical companies from the beginning to the end of their drug trials, the platform now adds Actigraph’s medical-grade wearables to its repertoire of supported devices, which previously included...
July 29, 2019
Last week, Eko Devices announced a new service that matches ECG and heart sound recordings with clinical data to help pinpoint novel drug-data combinations. The Silicon Valley startup is pitching the platform, called Eko Home, as a resource for clinical trials targeting new therapies.
The new platform is already seeing some action. According to the company, an ongoing Mayo Clinic study exploring...
July 10, 2019
Clover Health, an Alphabet-backed insurtech startup serving the Medicare Advantage market, announced this morning the launch of a new subsidiary unit that will be focused on using data from its members to drive drug development.
Much like its parent company uses machine learning and artificial intelligence to generate predictive health insights for its member population, Clover Therapeutics will...
July 9, 2019
Cloud-based computing could offer major benefits to pharmaceutical companies in the area of drug development as they grapple with rising costs and avalanches of data that need to be collected, analyzed and shared.
In particular, the technology could help streamline operations and develop business cases as to whether a drug is likely to be needed — or financially viable.
“If you’ve got big pots of...
July 1, 2019
It would be hard to discuss healthcare trends without talking about what this means for the behemoth pharma industry. Recently, new kid on the block digital health has started to turn heads in across this well-established sector with its potential for improving R&D, tracking real-world evidence and even creating a new type of medicine with digital therapeutics.
While digital promises the...
March 29, 2019
At MEDinIsrael 2019 this week, a conference in Tel Aviv sponsored by the Israeli Export Institute, Dr. Lena Granovsky, director of analytics and big data at Teva Pharmaceuticals, spoke on and off stage about the work the top Israeli pharma company has been doing in digital health. These topics included the company's recently FDA-cleared smart inhaler ProAir Digihaler, as well as more broad...
June 12, 2018
Medidata, a New York City-based company that offers cloud storage and data analytics services for clinical trials, announced today that it has acquired Shyft Analytics, maker of a cloud data analytics platform specifically designed for the pharma and biotech industries.
The transaction valued Shyft at $195 million, inclusive of Medidata’s prior 6 percent ownership in the analytics platform, to be...
April 20, 2018
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company’s total funds raised to over $200 million.
“We are very pleased with the response to the fundraising," Ken Mulvany,...